• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Manufacturing
    • Packaging
    • Development
    • Compliance
    • Top 25
    • Directory
    • Microsites
    • Events
    • More
  • Magazine
  • News
  • Manufacturing
  • Packaging
  • Development
  • Compliance
  • Top 25
  • Directory
  • Microsites
  • Events
  • Current / Back Issue
    Features
    Editorial
    Columns
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Subscribe Now
    Advertise Now
    Top Features
    Small Innovators & Niche CROs

    Focus on Science

    Rapid and Data Rich Chromatographic Method Development

    Preparing Your Post Pandemic Talent Strategy

    How Modern Near-Infrared Came to Be
    Breaking News
    Online Exclusives
    Industry News
    Collaborations & Alliances
    Promotions & Moves
    Trials & Filings
    Financial Reports
    Bio News & Views
    Custom Sourcing News
    Packaging & Tracking
    CRO News
    Live From Shows
    Top News
    Microbiologics Expands Virology Services

    ATMPS, Ori Biotech Integrate Digital Platform for Cell & Gene Therapies

    Executive Moves: Novavax

    Albumedix Completes Commercial-Scale Mfg. Facility Expansion

    Catalent Biologics Completes Madison Expansion
    APIs
    Aseptic Processing
    Cleaning Validation
    Clinical Trial Materials
    Cytotoxics and High Potency Manufacturing
    Equipment
    Excipients
    Extractables and Leachables
    Facilities
    Fill/Finish
    Lyophilization
    Parenterals
    Process Development
    Process Validation
    Risk Management
    Scale-up/ Technology Transfer
    Solid Dosage/ Creams/ Ointments

    Albumedix Completes Commercial-Scale Mfg. Facility Expansion

    Ensuring Pharma Manufacturing Quality

    Exploring ICP-MS expertise at Almac

    Catalent Biologics Completes Madison Expansion

    Ascendia Pharmaceuticals Poised for Expansion
    Capsules
    Cold Chain Management
    Injectables
    Logistics
    Serialization
    Solid Dosage / Semi-solids
    Supply Chain
    Vials

    Cryoport Acquires Critical Transport Solutions Australia

    PharmParts – This Makes Sense!

    Securing Your API Supply Chain: Three Keys to Success

    Enteris BioPharma: Custom Solutions – From Bench to Market

    The Benefits of Outsourcing Cold Storage
    Analytical Services
    Bioanalytical Services
    Bioassay Developement
    Biologics, Proteins, Vaccines
    Biosimilars
    Chemistry
    Clinical Trials
    Drug Delivery
    Drug Development
    Drug Discovery
    Formulation Development
    Information Technology
    Laboratory Testing
    Methods Development
    Microbiology
    Preclinical Outsourcing
    R&D
    Toxicology

    Microbiologics Expands Virology Services

    ATMPS, Ori Biotech Integrate Digital Platform for Cell & Gene Therapies

    Albumedix Completes Commercial-Scale Mfg. Facility Expansion

    Exploring ICP-MS expertise at Almac

    Catalent Biologics Completes Madison Expansion
    Filtration & Purification
    GMPs/GCPs
    Inspections
    QA/QC
    Regulatory Affairs
    Validation

    Ensuring Pharma Manufacturing Quality

    What Will Change at FDA for 2021?

    RBQM Comes of Age: COVID as a Catalyst for Change

    Post-Pandemic Regulations

    Enteris BioPharma: Custom Solutions – From Bench to Market
    Companies
    Categories
    Corporate Capabilities
    Add New Company
    Contract Service Directory Companies
    Aphena Pharma Solutions

    Quotient Sciences

    PCI Pharma Services

    Adare Pharma Solutions

    Emergent BioSolutions
    Companies
    News Releases
    Posters
    Brochures
    Services
    Videos
    Case Study
    White Papers
    Jobs
    Contract Service Directory Companies
    Almac Group

    PCI Pharma Services

    Alcami

    Reed-Lane

    Emergent BioSolutions
    Webinars
    Live From Shows
    • Magazine
      • Current / Back Issue
      • Features
      • Editorial
      • Columns
      • Editorial Guidelines
      • Subscribe Now
      • Advertise Now
      • Enewsletter Archive
      • Digital Edition
    • Directory
      • Companies
      • Categories
      • Corporate Capabilities
      • Add Your Company
    • Manufacturing
      • APIs
      • Aseptic Processing
      • Cleaning Validation
      • Clinical Trial Materials
      • Cytotoxics and High Potency Manufacturing
      • Equipment
      • Excipients
      • Extractables and Leachables
      • Facilities
      • Fill/Finish
      • Lyophilization
      • Parenterals
      • Process Development
      • Process Validation
      • Risk Management
      • Scale-up/ Technology Transfer
      • Solid Dosage/ Creams/ Ointments
      • cGMP Manufacture
    • Packaging
      • Capsules
      • Cold Chain Management
      • Injectables
      • Logistics
      • Serialization
      • Solid Dosage / Semi-solids
      • Supply Chain
      • Vials
    • Development
      • Analytical Services
      • Bioanalytical Services
      • Bioassay Developement
      • Biologics, Proteins, Vaccines
      • Biosimilars
      • Chemistry
      • Clinical Trials
      • Drug Delivery
      • Drug Development
      • Drug Discovery
      • Formulation Development
      • Information Technology
      • Laboratory Testing
      • Methods Development
      • Microbiology
      • Preclinical Outsourcing
      • R&D
      • Toxicology
    • Compliance
      • Filtration & Purification
      • GMPs/GCPs
      • Inspections
      • QA/QC
      • Regulatory Affairs
      • Validation
    • Top 25 Pharma & BioPharma
    • Contract Pharma Direct
    • Breaking News
    • Online Exclusives
    • Slideshows
    • Experts Opinions
    • Surveys
      • Outsourcing Survey
      • Salary Survey
    • Glossary
    • Videos
    • Podcasts
    • White Papers
    • Infographics
    • Contract Pharma Conference
      • Contract Pharma Conference
      • Speakers
      • Exhibitors
      • Conference Sessions
    • Supplier Microsite
      • Companies
      • News Releases
      • Posters
      • Brochures
      • Services
      • Videos
      • Case Study
      • White Papers
    • eBook
    • Webinars
    • Events
      • Industry Events
      • Live from Show Events
      • Webinars
    • Classifieds / Job Bank
      • Classifieds
      • Job Bank
    • About Us
      • About Us
      • Contact Us
      • Advertise With Us
      • Privacy Policy
      • Terms of Use
    Breaking News

    AbbVie & Harvard University Form Research Alliance

    Launch an effort to study and address emergent viral diseases.

    Related CONTENT
    • CordenPharma Enters Alliance with Nanos of South Korea
    • BioCentriq, Kytopen Enter Cell Therapy Alliance
    • Evotec, Takeda Enter Multi-RNA Target Alliance
    • Rentschler, Leukocare Extend Service Offering with U.S. Site
    • Gilead, Novo Nordisk Expand NASH Alliance
    Contract Pharma Staff08.26.20
    AbbVie and Harvard University have announced a $30 million collaborative research alliance, launching a multi-pronged effort at Harvard Medical School (HMS) to study and develop novel therapies against emergent viral infections, with a focus on those caused by coronaviruses and by viruses that lead to hemorrhagic fever.
     
    This collaboration aims to integrate fundamental biology into the preclinical and clinical development of new therapies for viral diseases that address a variety of therapeutic modalities. HMS has led several large-scale, coordinated research efforts launched at the beginning of the COVID-19 pandemic.
     
    "A key element of having a strong R&D organization is collaboration with top academic institutions, like Harvard Medical School, to develop therapies for patients who need them most," said Michael Severino, M.D., vice chairman and president, AbbVie. "There is much to learn about viral diseases and the best way to treat them. By harnessing the power of collaboration, we can develop new therapeutics sooner to ensure the world is better prepared for future potential outbreaks." 
     
    "The cataclysmic nature of the COVID-19 pandemic reminds us how vital it is to be prepared for the next public health crisis and how critical collaboration is on every level—across disciplines, across institutions, and across national boundaries," said George Q. Daley, M.D., Ph.D., dean of Harvard Medical School. "Harvard Medical School, as the nucleus of an ecosystem of fundamental discovery and therapeutic translation, is uniquely positioned to propel this transformative research alongside allies like AbbVie."
     
    Programs

    AbbVie will provide $30 million over three years and additional in-kind support leveraging AbbVie's scientists, expertise and facilities to advance collaborative research and early-stage development efforts across five program areas that address a variety of therapeutic modalities:
     
    1. Immunity and immunopathology—Study of the fundamental processes that impact the body's critical immune responses to viruses and identification of opportunities for therapeutic intervention.

    Led by Uli Von Andrian, M.D., Mallinckrodt professor of immunopathology in the Blavatnik Institute at HMS and Program Leader of Basic Immunology at the Ragon Institute of MGH, MIT, and Harvard; and by Jochen Salfeld, Ph.D., vice president, immunology and virology discovery at AbbVie.

    2. Host targeting for antiviral therapies—Development of approaches that modulate host proteins in an effort to disrupt the life cycle of emergent viral pathogens.

    Led by Pamela Silver, Ph.D., Elliot T. and Onie H. Adams professor of biochemistry and systems biology in the Blavatnik Institute at HMS; and by Steve Elmore, Ph.D., vice president, drug discovery science and technology at AbbVie.
     
    3. Antibody therapeutics—Rapid development of therapeutic antibodies or biologics against emergent pathogens, including SARS-CoV-2, to a preclinical or early-clinical stage.

    Led by Jonathan Abraham, MD, PhD, assistant professor of microbiology in the Blavatnik Institute at HMS; and by Jochen Salfeld, Ph.D., vice president, immunology and virology discovery at AbbVie.
     
    4. Small molecules—Discovery and early-stage development of small-molecule drugs that would act to prevent replication of known coronaviruses and emergent pathogens.

    Led by Mark Namchuk, PhD, executive director of therapeutics translation at HMS and senior lecturer of biological chemistry and molecular pharmacology in the Blavatnik Institute at HMS; and by Steve Elmore, Ph.D., vice president, drug discovery science and technology at AbbVie. 
     
    5. Translational development—Preclinical validation, pharmacological testing, and optimization of leading approaches, in collaboration with Harvard-affiliated hospitals, with program leads to be determined.
    Related Searches
    • R&D
    Suggested For You
    CordenPharma Enters Alliance with Nanos of South Korea CordenPharma Enters Alliance with Nanos of South Korea
    BioCentriq, Kytopen Enter Cell Therapy Alliance BioCentriq, Kytopen Enter Cell Therapy Alliance
    Evotec, Takeda Enter Multi-RNA Target Alliance Evotec, Takeda Enter Multi-RNA Target Alliance
    Rentschler, Leukocare Extend Service Offering with U.S. Site Rentschler, Leukocare Extend Service Offering with U.S. Site
    Gilead, Novo Nordisk Expand NASH Alliance Gilead, Novo Nordisk Expand NASH Alliance
    Phlow Corp. and USP Form Alliance Phlow Corp. and USP Form Alliance
    Altasciences Contributes to Vibegron Approval Altasciences Contributes to Vibegron Approval
    Strategic Alliance Management Virtual Congress Strategic Alliance Management Virtual Congress
    Executive Moves at Frontage Executive Moves at Frontage
    Jubilant Biosys, Yale Form Research Alliance Jubilant Biosys, Yale Form Research Alliance
    Pfizer Pfizer's 4Q Revenues up 12%
    Imcyse, Pfizer Enter Autoimmune Research Alliance Imcyse, Pfizer Enter Autoimmune Research Alliance
    BioMed X, Janssen Enter Oral Drug Delivery Alliance BioMed X, Janssen Enter Oral Drug Delivery Alliance
    Pfizer, BioNTech Enter Vax Pact with COVAX  Pfizer, BioNTech Enter Vax Pact with COVAX
    Metrion, LifeArc Extend Neuroscience Alliance Metrion, LifeArc Extend Neuroscience Alliance

    Related Breaking News

    • Breaking News | R&D
      JSR Life Sciences Unveils Corporate Venture Fund

      JSR Life Sciences Unveils Corporate Venture Fund

      Aims to foster investment in new companies and innovative technologies.
      Charles Sternberg, Assistant Editor 03.24.21

    • Bio News | Breaking News | Collaborations & Alliances | CRO News | Drug Development | Drug Discovery | Industry News | R&D
      Innoforce and dMed Enter Development Collaboration

      Innoforce and dMed Enter Development Collaboration

      Aims to accelerate the development of innovative therapeutics.
      Tim Wright, Editor, Contract Pharma 03.03.21

    • Breaking News | CRO News | Drug Discovery | Industry News | R&D
      Icon to Acquire PRA Health Sciences

      Icon to Acquire PRA Health Sciences

      Brings together two organizations to create a leading healthcare intelligence and clinical CRO.
      Charles Sternberg, Assistant Editor 03.01.21


    • Analytical Services | Breaking News | Drug Discovery | Facilities | Industry News | R&D
      CatSci Opens New Site in UK

      CatSci Opens New Site in UK

      Strengthens analytical capabilities with the opening of a secondary site in Dagenham backed by a $4.2 million investment.
      Tim Wright, Editor, Contract Pharma 02.25.21

    • Analytical Services | Bioanalytical Services | Breaking News | Chemistry | Facilities | Industry News | Laboratory Testing | R&D
      Almac Group Completes $7M R&D Center

      Almac Group Completes $7M R&D Center

      Significant expansion of biocatalysis, flow chemistry, and peptide capacity.
      Tim Wright, Editor, Contract Pharma 02.23.21

    • Breaking News | R&D
      Wavelength Pharmaceuticals Acquires Majority Stake in Vanamali Organics

      Wavelength Pharmaceuticals Acquires Majority Stake in Vanamali Organics

      Further strengthens its drug substance manufacturing footprint and global supply chain.
      Charles Sternberg, Assistant Editor 02.18.21


    • Breaking News | Collaborations & Alliances | CRO News | Drug Discovery | Industry News | R&D
      Jubilant Biosys, Yale Form Research Alliance

      Jubilant Biosys, Yale Form Research Alliance

      Aims to accelerate small molecule discovery programs leveraging Jubilant's medicinal chemistry, structural biology, in-vitro and in-vivo pharmacology.
      02.10.21

    • Breaking News | Collaborations & Alliances | Drug Discovery | Industry News | R&D
      Almac Sciences Secures Support from Invest NI

      Almac Sciences Secures Support from Invest NI

      Accelerates enzyme discovery program.
      Contract Pharma Staff 01.13.21

    • Breaking News | Collaborations & Alliances | Drug Discovery | Industry News | R&D
      Mogrify Enters Research Collaboration with MRC LMB

      Mogrify Enters Research Collaboration with MRC LMB

      Research project aims to develop novel protein expression systems via cell reprogramming.
      Contract Pharma Staff 01.11.21


    • Breaking News | cGMP Manufacture | Drug Development | Industry News | R&D
      Ascentage Selects PharmaBlock as Preferred Provider

      Ascentage Selects PharmaBlock as Preferred Provider

      PharmaBlock will support Ascentage in accelerating its drug development pipeline with R&D, manufacturing capacity, and technological solutions.
      Contract Pharma Staff 12.11.20

    • Breaking News | Collaborations & Alliances | CRO News | Drug Discovery | Industry News | R&D
      Evotec and Sartorius Partner with Curexsys

      Evotec and Sartorius Partner with Curexsys

      Leverage IPSC platform for scalable manufacturing of Curexsys' exosome-based therapeutics.
      Contract Pharma Staff 12.09.20

    • Breaking News | CRO News | Industry News | R&D
      LINK Medical Acquires IRW Consulting AB

      LINK Medical Acquires IRW Consulting AB

      Strengthens its position in the Nordics while improving its offerings and capabilities.
      Contract Pharma Staff 12.09.20


    • Breaking News | Industry News | R&D
      Colorcon Ventures Invests in i20 Therapeutics

      Colorcon Ventures Invests in i20 Therapeutics

      Will work together to accelerate i2O’s research and development efforts.
      Contract Pharma Staff 12.07.20

    • Breaking News | CRO News | Facilities | Industry News | R&D
      Reach Separations Expands Nottingham Premises

      Reach Separations Expands Nottingham Premises

      Responds to increased demand for its chiral purification services.
      Contract Pharma Staff 11.03.20

    • Bioanalytical Services | Breaking News | CRO News | R&D
      TherapeutAix Expands R&D Network

      TherapeutAix Expands R&D Network

      Adds CROs Alderley Analytical and Peak Proteins to address Pharmacokinetics and Pharmacodynamics challenges for clients.
      Contract Pharma Staff 10.29.20

    Trending
    • Astellas, Affinivax In Global MAPS Vax Pact
    • Ascendia Pharmaceuticals Poised For Expansion
    • Sanofi To Build New $700M Flu Vaccine Facility In Canada
    • Catalent Biologics Completes Madison Expansion
    • ANI Acquires Branded Products Portfolio From Sandoz
    Breaking News
    • Microbiologics Expands Virology Services
    • ATMPS, Ori Biotech Integrate Digital Platform for Cell & Gene Therapies
    • Executive Moves: Novavax
    • Albumedix Completes Commercial-Scale Mfg. Facility Expansion
    • Catalent Biologics Completes Madison Expansion
    View Breaking News >
    CURRENT ISSUE

    April 2021

    • Small Innovators & Niche CROs
    • Focus on Science
    • Rapid and Data Rich Chromatographic Method Development
    • Preparing Your Post Pandemic Talent Strategy
    • How Modern Near-Infrared Came to Be
    • Securing Your API Supply Chain: Three Keys to Success
    • View More >

    Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
    You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

    • About Us
    • Privacy Policy
    • Terms And Conditions
    • Contact Us

    follow us

    Subscribe
    Nutraceuticals World

    Latest Breaking News From Nutraceuticals World

    Four-Week Fish Oil Regimen Showed Significant Muscular Damage Protection in Recent Study
    Review Covers Role of Vitamin K2 in the ‘Calcium Paradox’
    KD Pharma Acquires Rohner AG Manufacturing Assets
    Coatings World

    Latest Breaking News From Coatings World

    Jebsen & Jessen, Innospec Sign Distribution Agreement
    Shepherd Color Unveils Bismuth Vanadate Yellow Pigment
    HMG Paints Reports Positive Feedback on Contract Matt Emulsion
    Medical Product Outsourcing

    Latest Breaking News From Medical Product Outsourcing

    BioSig Launches Software Update for PURE EP Electrophysiology Platform
    Katena Acquires Ophthalmic Surgical Instrument Maker ASICO
    Vicarious Surgical Appoints CFO and Chief Legal Officer
    Contract Pharma

    Latest Breaking News From Contract Pharma

    Microbiologics Expands Virology Services
    ATMPS, Ori Biotech Integrate Digital Platform for Cell & Gene Therapies
    Executive Moves: Novavax
    Beauty Packaging

    Latest Breaking News From Beauty Packaging

    Cosmoprof Worldwide Bologna Postpones 2021 Show
    Native Launches Broad Spectrum SPF 30 Mineral Sunscreens
    Revieve Launches Skin Coach
    Happi

    Latest Breaking News From Happi

    BASF Increases Price of Kaolin
    Kao Launches Online Beauty Store in Europe
    Neutrogena Takes Action on Skin Health Disparities
    Ink World

    Latest Breaking News From Ink World

    Kumon North America Adds Speedmaster XL 106 from Heidelberg
    SE-DA Invests in Kornit Presto S
    Acrylic Resins Market Worth $21.9 Billion by 2025: MarketsandMarkets
    Label & Narrow Web

    Latest Breaking News From Label & Narrow Web

    Maxcess updates user interface for Fife guiding Sensor
    Bobst announces virtual packaging industry event
    Edale appoints agent in Poland
    Nonwovens Industry

    Latest Breaking News From Nonwovens Industry

    PFNonwovens Adding New Capabilities in Znojmo
    Russ Torres Named Group President of Kimberly-Clark North America
    Aries Face Masks Meet ASTM Standards
    Orthopedic Design & Technology

    Latest Breaking News From Orthopedic Design & Technology

    Global Bone Tumor Ablation Devices Market to Top $111 Million by 2027
    GreenBone Ortho Closes 10 Million Euros Series B Funding Round
    SynerFuse, Cirtec Medical Partner to Develop Back Pain Management Device
    Printed Electronics Now

    Latest Breaking News From Printed Electronics Now

    Virtual ASMC 2021 Spotlights Advanced Semiconductor Manufacturing Excellence
    European Commission's Innovation Radar Acknowledges 3 ARMOR Innovations
    SUPERSMART Wins 'Best Publicly Funded Project Demonstrator' in 2021 OE-A Competition

    Copyright © 2021 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

    AD BLOCKER DETECTED

    Our website is made possible by displaying online advertisements to our visitors.
    Please consider supporting us by disabling your ad blocker.


    FREE SUBSCRIPTION Already a subscriber? Login